130 related articles for article (PubMed ID: 10360381)
1. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine.
Van Den Neste E; Bontemps F; Delacauw A; Cardoen S; Louviaux I; Scheiff JM; Gillis E; Leveugle P; Deneys V; Ferrant A; Van den Berghe G
Leukemia; 1999 Jun; 13(6):918-25. PubMed ID: 10360381
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia.
Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB
Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937
[TBL] [Abstract][Full Text] [Related]
3. 2-Chloro-2'-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes.
Van Den Neste E; Cardoen S; Husson B; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
Leukemia; 2002 Jan; 16(1):36-43. PubMed ID: 11840261
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
5. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
[TBL] [Abstract][Full Text] [Related]
6. Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
Callea I; Console G; Sculli G; Filangeri M; Messina G; Morabito F
Haematologica; 1998 Aug; 83(8):756-7. PubMed ID: 9793266
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.
Lindemalm S; Liliemark J; Gruber A; Eriksson S; Karlsson MO; Wang Y; Albertioni F
Haematologica; 2003 Mar; 88(3):324-32. PubMed ID: 12651272
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2'-deoxyadenosine.
Bontemps F; Delacauw A; Cardoen S; Van Den Neste E; Van Den Berghe G
Biochem Pharmacol; 2000 May; 59(10):1237-43. PubMed ID: 10736424
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Van Den Neste E; Louviaux I; Michaux JL; Delannoy A; Michaux L; Sonet A; Bosly A; Doyen C; Mineur P; André M; Straetmans N; Coche E; Venet C; Duprez T; Ferrant A
Leukemia; 2000 Jun; 14(6):1136-42. PubMed ID: 10865980
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB.
Smal C; Lisart S; Maerevoet M; Ferrant A; Bontemps F; Van Den Neste E
Biochem Pharmacol; 2007 Feb; 73(3):351-8. PubMed ID: 17137556
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
Beck FW; Eilender DS; Dandashi MH; Siddiq F; Snell DC; Godmere MA; Al-Katib AM; Mohammad RM
Int J Mol Med; 2004 Jul; 14(1):113-9. PubMed ID: 15202025
[TBL] [Abstract][Full Text] [Related]
15. Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.
Cardoen S; Van Den Neste E; Smal C; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
Clin Cancer Res; 2001 Nov; 7(11):3559-66. PubMed ID: 11705877
[TBL] [Abstract][Full Text] [Related]
16. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
17. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
[TBL] [Abstract][Full Text] [Related]
18. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
19. Comparison of infrared spectra of CLL cells with their ex vivo sensitivity (MTT assay) to chlorambucil and cladribine.
Liu KZ; Schultz CP; Johnston JB; Lee K; Mantsch HH
Leuk Res; 1997; 21(11-12):1125-33. PubMed ID: 9444947
[TBL] [Abstract][Full Text] [Related]
20. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
